학술논문
Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial
Document Type
Article
Author
Source
In: The Lancet Infectious Diseases . (The Lancet Infectious Diseases, March 2024, 24(3):308-318)
Subject
Language
English
ISSN
14744457
14733099
14733099